Vericiguat

CHEMBL4066936 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

426.4 g/mol

LogP

1.5

Phase

4

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator that directly activates sGC independent of nitric oxide (NO) availability and sensitizes sGC to low levels of NO, increasing cyclic GMP (cGMP) production in vascular smooth muscle and cardiomyocytes. It is approved for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event. Increased cGMP mediates vasodilation, reduced cardiac afterload, and cardioprotective signaling.

Masse moléculaire

426,4000 g/mol

LogP

1,50

TPSA

147,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Cardiovascular Disease Obesity Hypertension Breast Cancer Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N

InChI

InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)

Molecular Formula

C19H16F2N8O2

HBD / HBA

3 / 10

Liaisons Rotatives

5

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator that directly activates sGC independent of nitric oxide (NO) availability and sensitizes sGC to low levels of NO, increasing cyclic GMP (cGMP) production in vascular smooth muscle and cardiomyocytes. It is approved for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event. Increased cGMP mediates vasodilation, reduced cardiac afterload, and cardioprotective signaling.

Yes, Vericiguat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4066936. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 54674461. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Vericiguat sur PillFYI

Structure

Données Clés

Formule: C19H16F2N8O2
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.